TIM
NVAX icon

Timelo Investment Management’s Novavax NVAX Stock Holding History

Timelo Investment Management’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-5,000
Closed -$368K – 81
2022
Q1 		$368K Sell
5,000
-5,000
-50% -$446K 0.27% 76
2021
Q4 		$1.43M Buy
+10,000
New +$1.72M 0.77% 36

Other funds holding NVAX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Voloridge Investment Management
Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Timelo Investment Management's NVAX Position: Q2 2022 in Review

Timelo Investment Management sold out of Novavax (NVAX) in Q2 2022, closing a stake of 5,000 shares — an estimated $368K sold.

Timelo Investment Management first reported a position in NVAX in Q4 2021 and held it in 2 quarters. The position peaked at $1.43M in Q4 2021. 325 funds tracked by Wall St. Rank hold NVAX as of Q2 2022.

  • Timelo Investment Management reported no remaining Novavax position as of Q2 2022 after selling out during the quarter.
  • Timelo Investment Management sold 5,000 Novavax shares in Q2 2022, an estimated $368K.
  • Timelo Investment Management first reported a position in Novavax in Q4 2021 and held it in 2 quarters.
  • Timelo Investment Management's Novavax position peaked at $1.43M in Q4 2021.
  • 325 funds tracked by Wall St. Rank held Novavax as of Q2 2022.

Based on Timelo Investment Management's 13F filing for Q2 2022, filed 1 Aug 2022.